Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...

And Eli Lilly's cloud also has a pair of silver linings that investors ... Lilly's newest cash cow, tirzepatide -- a therapy ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...